About this item:

79 Views | 43 Downloads

Author Notes:

Rui Moreno, Email: r.moreno@mail.telepac.pt

RM, AR and JLV wrote the first draft. The text was revised by LP, GHP, JT, HBG, MT, CMC, SNM, MS, ER, HCP, MS, JFT, DWDL, CJ, JJDW, GSM, CS, EA, TF and ASM. All authors read and approved the final text.

RM has no competing interest to declare relevant to this article. AR has no competing interest to declare relevant to this article. LP has no competing interest to declare relevant to this article. GH has no competing interest to declare relevant to this article. JT has no competing interest to declare relevant to this article. HBG received funding from Gilead Sciences, Inc. to serve on COVID therapeutics advisory board (not related to this work). MT has no competing interest to declare relevant to this article. CMC is an Associate Editor of Critical Care—he has no other competing interest to declare relevant to this article. SNM has no competing interest to declare relevant to this article. Mervyn S has no competing interest to declare relevant to this article. ER has no competing interest to declare relevant to this article. HCP served on the surviving sepsis campaign guidelines and is physician-lead for a Michigan statewide sepsis consortium. This manuscript does not represent the views of the Department of Veterans Affairs or the US government. This material is the result of work supported with resources and use of facilities at the Ann Arbor VA Medical Center. Marcio S is founder and equity shareholder of Epimed Solutions®, which commercializes the Epimed Monitor System®, a cloud-based software for ICU management and benchmarking. JFT has no competing interest to declare relevant to this article. DWdL has no competing interest to declare relevant to this article. CJ has no competing interest to declare relevant to this article. JJDW has no competing interest to declare relevant to this article. GSM has no competing interest to declare relevant to this article. CS has no competing interest to declare relevant to this article. EA has no competing interest to declare relevant to this article. AR has no competing interest to declare relevant to this article. TF has no competing interest to declare relevant to this article. ASM has no competing interest to declare relevant to this article. JLV is Editor-in-Chief of Critical Care—he has no other competing interest to declare relevant to this article.

Subjects:

Research Funding:

JJDW is supported by a Senior Clinical Investigator Grant from the Research Foundation Flanders (FWO, Ref. 1881020N).

No external funding.

Keywords:

  • Humans
  • Organ Dysfunction Scores
  • Critical Illness
  • Prognosis
  • Multiple Organ Failure

The Sequential Organ Failure Assessment (SOFA) Score: has the time come for an update?

Show all authors Show less authors

Tools:

Journal Title:

Critical Care

Volume:

Volume 27, Number 1

Publisher:

, Pages 15-15

Type of Work:

Article | Final Publisher PDF

Abstract:

The Sequential Organ Failure Assessment (SOFA) score was developed more than 25 years ago to provide a simple method of assessing and monitoring organ dysfunction in critically ill patients. Changes in clinical practice over the last few decades, with new interventions and a greater focus on non-invasive monitoring systems, mean it is time to update the SOFA score. As a first step in this process, we propose some possible new variables that could be included in a SOFA 2.0. By so doing, we hope to stimulate debate and discussion to move toward a new, properly validated score that will be fit for modern practice.

Copyright information:

© The Author(s) 2023

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/rdf).
Export to EndNote